Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2020 20:35 ET | Source: Junshi Biosciences

Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

SHANGHAI, China, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
August 30, 2020 20:00 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates

-- Supplemental NDAs for Toripalimab filed-- Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies-- Dual Listing on the STAR Market SHANGHAI,...
August 20, 2020 10:45 ET | Source: Junshi Biosciences

Junshi Biosciences and Impact Therapeutics Establish Joint Venture to Develop PARP Inhibitor Senaparib (IMP4297) in China

SHANGHAI and NANJING, China, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery,...
August 09, 2020 22:07 ET | Source: Junshi Biosciences

TopAlliance Appoints Patricia Keegan, M.D., as Chief Medical Officer

ROCKVILLE, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- TopAlliance Biosciences, a wholly own subsidiary of Shanghai Junshi Biosciences (HKEX: 1877; SSE: 688180) today announced the appointment of Dr....
July 12, 2020 20:00 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
July 12, 2020 08:20 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Approval of “B” Marker Removal from Company’s Stock Name by HKEX

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
June 07, 2020 11:30 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China

First healthy volunteer has been dosed in a Phase I study of JS016, the first SARS-CoV-2 neutralizing antibody to enter the clinical stage in ChinaJunshi and Lilly will co-develop JS016 globallyJS016...
June 01, 2020 10:50 ET | Source: Junshi Biosciences

Junshi Biosciences and Merck Announce Collaboration to Explore Promising New COMBINATION Treatment for Head and Neck Cancer Patients in China

SHANGHAI, China, June 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEK: 1877), a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel...
May 26, 2020 10:10 ET | Source: Junshi Biosciences

Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

CB6 demonstrated prophylactic and treatment effects in rhesus monkeys Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company SHANGHAI, China, May 26, 2020...
May 07, 2020 18:10 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma

SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization...